头孢托罗：临床观察。
Ceftobiprole: a clinical view.
机构信息
Luis Eduardo López Cortés. Unidad de Gestión Clínica de Enfermedades Infecciosas y Microbiología. Hospital Universitario Virgen Macarena. Instituto de Biomedicina de Sevilla (IBIS). Seville, Spain.
出版信息
Rev Esp Quimioter. 2021 Sep;34 Suppl 1(Suppl1):32-34. doi: 10.37201/req/s01.09.2021. Epub 2021 Sep 30.
Abstract
Ceftobiprole is a broad-spectrum, fifth-generation cephalosporin currently approved for community-acquired and non-ventilator-associated hospital-acquired pneumonia. High bactericidal and anti-biofilm activity has been exhibited in in vitro and animal models. This, together with its synergism with other antibiotics against gram-positive bacteria, makes it an ideal candidate for treatment of complex infections, such as those associated with devices or infective endocarditis. More clinical data are needed to achieve drug positioning.
摘要
头孢托罗匹酯是一种广谱、第五代头孢菌素，目前已被批准用于社区获得性和非呼吸机相关性医院获得性肺炎。在体外和动物模型中均表现出了高杀菌和抗生物膜活性。此外，它与其他抗生素对革兰氏阳性菌的协同作用使其成为治疗复杂感染的理想候选药物，如与器械相关或感染性心内膜炎相关的感染。需要更多的临床数据来实现药物定位。
相似文献
1
Ceftobiprole: a clinical view.头孢托罗：临床观察。
Rev Esp Quimioter. 2021 Sep;34 Suppl 1(Suppl1):32-34. doi: 10.37201/req/s01.09.2021. Epub 2021 Sep 30.
2
Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.头孢托罗：一种新型、广谱头孢菌素，对耐甲氧西林金黄色葡萄球菌有活性。
Am J Health Syst Pharm. 2010 Jun 15;67(12):983-93. doi: 10.2146/ajhp090285.
3
Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.头孢比普甲磺酸盐：BAL5788、JNJ 30982081、JNJ30982081、RO 65-5788、RO 655788。
Drugs R D. 2006;7(5):305-11. doi: 10.2165/00126839-200607050-00003.
4
Ceftobiprole: in-vivo profile of a bactericidal cephalosporin.头孢比普：一种杀菌性头孢菌素的体内概况
Clin Microbiol Infect. 2006 Apr;12 Suppl 2:17-22. doi: 10.1111/j.1469-0691.2006.01404.x.
5
Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.头孢托罗匹酯：在治疗医院获得性或社区获得性肺炎患者中的应用评价。
Drugs. 2014 Sep;74(13):1523-42. doi: 10.1007/s40265-014-0273-x.
6
Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).头孢比普：一种新型头孢菌素，对革兰氏阳性和革兰氏阴性病原体均有活性，包括耐甲氧西林金黄色葡萄球菌（MRSA）。
Int J Antimicrob Agents. 2009 Jul;34(1):1-7. doi: 10.1016/j.ijantimicag.2008.12.012. Epub 2009 Mar 3.
7
Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).头孢洛林在对抗 2016-2017 年美国血流感染主要致病菌时的活性。
Diagn Microbiol Infect Dis. 2019 Jul;94(3):304-313. doi: 10.1016/j.diagmicrobio.2019.01.015. Epub 2019 Jan 26.
8
Ceftobiprole: a new broad spectrum cephalosporin.头孢比普：一种新型广谱头孢菌素。
Expert Opin Pharmacother. 2009 Jul;10(10):1675-86. doi: 10.1517/14656560903048967.
9
In vitro activity of ceftaroline and ceftobiprole against clinical isolates of Gram-positive bacteria from infective endocarditis: are these drugs potential options for the initial management of this disease?头孢洛林和头孢托罗匹酯对感染性心内膜炎临床分离革兰阳性菌的体外活性：这些药物是否是该疾病初始治疗的潜在选择？
Diagn Microbiol Infect Dis. 2020 Dec;98(4):115153. doi: 10.1016/j.diagmicrobio.2020.115153. Epub 2020 Jul 28.
10
Mechanisms of action and antimicrobial activity of ceftobiprole.头孢比普的作用机制与抗菌活性
Rev Esp Quimioter. 2019 Sep;32 Suppl 3(Suppl 3):3-10.
引用本文的文献
1
Ceft-to-Ceft Study: Real-Life Experience with Ceftaroline and Ceftobiprole in Treatment of the Principal Infectious Syndromes in a Spanish Multicenter Hospital Cohort.头孢洛林与头孢比普的对比研究：西班牙多中心医院队列中头孢洛林和头孢比普治疗主要感染综合征的真实生活经验
Antibiotics (Basel). 2023 Dec 2;12(12):1692. doi: 10.3390/antibiotics12121692.
2
New antibiotics for Gram-negative pneumonia.用于治疗革兰氏阴性肺炎的新型抗生素。
Eur Respir Rev. 2022 Dec 21;31(166). doi: 10.1183/16000617.0119-2022. Print 2022 Dec 31.
3
Investigational agents for the treatment of methicillin-resistant (MRSA) bacteremia: progress in clinical trials.治疗耐甲氧西林金黄色葡萄球菌（MRSA）菌血症的研究性药物：临床试验进展。
Expert Opin Investig Drugs. 2022 Mar;31(3):263-279. doi: 10.1080/13543784.2022.2040015. Epub 2022 Feb 14.
本文引用的文献
1
Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry.在加拿大应用头孢托罗匹酯的真实临床经验：来自 CLEAR（加拿大抗菌药物真实世界应用领导力）注册研究的结果。
J Glob Antimicrob Resist. 2021 Mar;24:335-339. doi: 10.1016/j.jgar.2021.01.014. Epub 2021 Feb 1.
2
Ceftobiprole for Treatment of MRSA Blood Stream Infection: A Case Series.头孢比普治疗耐甲氧西林金黄色葡萄球菌血流感染：病例系列
Infect Drug Resist. 2020 Aug 3;13:2667-2672. doi: 10.2147/IDR.S254395. eCollection 2020.
3
Real-life experience with ceftobiprole in a tertiary-care hospital.在一家三级保健医院使用头孢托罗匹酯的真实临床经验。
J Glob Antimicrob Resist. 2020 Sep;22:386-390. doi: 10.1016/j.jgar.2020.03.010. Epub 2020 Apr 1.
4
Ceftobiprole versus daptomycin in bacteremia: a novel protocol for a double-blind, Phase III trial.头孢洛林对比达托霉素治疗菌血症：一项双盲、III 期试验的新方案。
Future Microbiol. 2020 Jan;15(1):35-48. doi: 10.2217/fmb-2019-0332. Epub 2020 Jan 10.
5
Ceftobiprole for the treatment of infective endocarditis: A case series.头孢洛林治疗感染性心内膜炎：病例系列。
J Glob Antimicrob Resist. 2020 Mar;20:56-59. doi: 10.1016/j.jgar.2019.07.020. Epub 2019 Jul 24.
6
Bactericidal activity of ceftobiprole combined with different antibiotics against selected Gram-positive isolates.头孢托罗与不同抗生素联合对选定革兰氏阳性分离株的杀菌活性。
Diagn Microbiol Infect Dis. 2019 Jan;93(1):77-81. doi: 10.1016/j.diagmicrobio.2018.07.015. Epub 2018 Sep 14.
7
Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).头孢比普与对照药物在针对2015年从欧洲收集的当代革兰氏阳性和阴性菌进行测试时的抗菌活性。
Diagn Microbiol Infect Dis. 2018 May;91(1):77-84. doi: 10.1016/j.diagmicrobio.2017.12.020. Epub 2018 Jan 3.
8
A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.头孢比普甲磺酸盐与头孢他啶加利奈唑胺治疗医院获得性肺炎的3期随机双盲对照试验
Clin Infect Dis. 2014 Jul 1;59(1):51-61. doi: 10.1093/cid/ciu219. Epub 2014 Apr 9.
9
Evaluation of the in vitro activities of ceftobiprole and comparators in staphylococcal colony or microtitre plate biofilm assays.评估头孢托罗匹酯及对照药物在葡萄球菌集落或微量滴定板生物膜检测中的体外活性。
Int J Antimicrob Agents. 2014 Jan;43(1):32-9. doi: 10.1016/j.ijantimicag.2013.09.013. Epub 2013 Oct 24.
10
A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.一项比较头孢托罗匹酯美他醇与头孢曲松及联用或不联用利奈唑胺治疗需要住院治疗的社区获得性肺炎患者的随机、双盲临床试验。
Int J Antimicrob Agents. 2012 Mar;39(3):240-6. doi: 10.1016/j.ijantimicag.2011.11.005. Epub 2012 Jan 9.
Zotero 插件